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Abstract
Bacteroides thetaiotaomicron is a dominant member of the human intestinal microbiome.
The genome of this anaerobe encodes more than 100 proteolytic enzymes, the majority of
which have not been characterized. In the present study, we have produced and purified
recombinant dipeptidyl peptidase III (DPP III) from B. thetaiotaomicron for the purposes of
biochemical and structural investigations. DPP III is a cytosolic zinc-metallopeptidase of the
M49 family, involved in protein metabolism. The biochemical results for B. thetaiotaomicron
DPP III from our research showed both some similarities to, as well as certain differences
from, previously characterised yeast and human DPP III. The 3D-structure of B. thetaiotao-
micron DPP III was determined by X-ray crystallography and revealed a two-domain protein.
The ligand-free structure (refined to 2.4 Å) was in the open conformation, while in the pres-
ence of the hydroxamate inhibitor Tyr-Phe-NHOH, the closed form (refined to 3.3 Å) was
observed. Compared to the closed form, the two domains of the open form are rotated away
from each other by about 28 degrees. A comparison of the crystal structure of B. thetaiotao-
micron DPP III with that of the human and yeast enzymes revealed a similar overall fold.
However, a significant difference with functional implications was discovered in the upper
domain, farther away from the catalytic centre. In addition, our data indicate that large pro-
tein flexibility might be conserved in the M49 family.
Introduction
Bacteroides thetaiotaomicron is one of the best studied representatives of the Bacteroides spp, a
group of anaerobic, Gram-negative microbes, which are part of the human intestinal micro-
biome and play a central role in symbiotic host-bacterial relationships in the human gut [1].
These bacteria are known for their ability to degrade a wide variety of glycans that are not
substrates for human glycosidases. The completed genome sequence of B. thetaiotaomicron
revealed that a large fraction of the 4779 encoded proteins participate in harvesting otherwise
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indigestible dietary polysaccharides and in metabolizing their liberated sugars (e.g. 172 glycosyl
hydrolases, 163 homologues of SusC and SusD outer membrane polysaccharide-binding pro-
teins; 20 sugar-specific transporters) [2]. The genome sequence also provided insight into the
proteolytic capacity of B. thetaiotaomicron: according to the MEROPS database (http://merops.
sanger.ac.uk/; release 11.0) [3], this bacterium possesses 129 peptidases. The majority of these
peptidases have not been functionally or biochemically characterized.
Recently, we have cloned and biochemically characterized dipeptidyl peptidase III (DPP
III) from B. thetaiotaomicron [4]. DPP III (EC 3.4.14.4; earlier names: dipeptidyl arylamidase
III, dipeptidyl aminopeptidase III) is a cytosolic zinc-metallopeptidase of the M49 family [3].
This exopeptidase catalyses the hydrolysis of the penultimate peptide bond of its oligopeptide
substrates with unsubstituted N-termini, thereby sequentially removing N-terminal dipeptides
[5, 6]. It is broadly distributed in eukaryotic cells and considered to participate in normal
intracellular protein catabolism. In addition to its proteolytic activity, the mammalian enzyme
appears to be involved in cellular defence against oxidative stress as an activator in the
Keap1-Nrf2 signalling pathway [7, 8].
The M49 family of metallopeptidases (DPP III family) is defined by five conserved amino
acid sequence regions, including the unique hexapeptide zinc-binding motif, HEXXGH [9,
10]. A second conserved motif involved in the coordination of the active-site zinc, EEXR(K)
AE(D), is situated 22–55 amino acids toward the C-terminus from the first one [10]. Until
now, three-dimensional structures of two eukaryotic DPP III enzymes have been solved: yeast
and human DPP III, respectively [11, 12]. The crystal structures of ligand-free human and
yeast enzymes revealed an elongated protein molecule with two domains separated by a wide
cleft, as well as a very similar overall fold. The X-ray structure of human DPP III in complex
with the pentapeptide tynorphin showed that ligand binding was accompanied by a large
domain motion and a closure of the inter-domain cleft [12].
In silico analyses of the amino acid sequences of the M49 family peptidases revealed low
similarity of the bacterial sequences with the eukaryotic ones. In all eukaryotic DPPs III, the
second zinc-binding motif contained a cysteine residue (EECRAE), while the majority of the
bacterial sequences contained a cysteine in the first motif (HECLGH) [4]. In order to investi-
gate the properties of the bacterial orthologues of the M49 family, we cloned and heterolo-
gously expressed the cDNA encoding full-length DPP III from B. thetaiotaomicron (BtDPP III,
675 amino acids), biochemically characterized the purified recombinant protein and com-
pared it to the human enzyme [4]. BtDPP III is a monomeric acidic protein (Mr ~ 76000, pI
~5.1) which hydrolyses the preferred synthetic substrate of mammalian DPPs III, Arg-Arg-
2-naphthylamide (Arg2-2NA), with a pH optimum of 8.0. The hydrolytic activity of purified
BtDPP III is, similarly to that of the eukaryotic enzymes, enhanced when Co2+ ions are added
to the reaction mixture, and abolished in the presence of chelating agents and sulfhydryl
reagents [4]. Compared to its human counterpart, the bacterial enzyme differed in its pHhH
optimum and kinetic parameters for Arg2-2NA hydrolysis (3-fold lower Km value and 6-fold
lower kcat value determined with BtDPP III). Furthermore, we observed some differences in
the inhibitory potency of novel dipeptidyl hydroxamic acids [13].
We performed this study to gain insight into the three-dimensional structure of BtDPP III,
to be able to compare it with its human counterpart and to establish the structural determi-
nants of the similarities/differences between them. Aside from its symbiotic role, B. thetaiotao-
micron is also known as an opportunistic pathogen, which is of clinical interest [4]. In general,
Bacteroides species are significant clinical pathogens when they escape the gut environment.
We propose that DPP III is involved in protein metabolism in B. thetaiotaomicron and in
many other Bacteroides species and that it contributes to the growth of these bacteria. In addi-
tion, the aim of this study was to find out whether large protein flexibility is conserved in the
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DPP III family. Here, we describe for the first time the three-dimensional structure of the bac-
terial orthologue of the M49 family in both open and closed conformations. Our results
revealed that the overall protein fold is very similar to that of the human and yeast orthologue,
with two domains separated by a wide cleft containing a catalytic zinc ion. However, signifi-
cant structural differences in the bacterial protein were observed in both the upper and the
lower domain.
Materials and methods
Cloning and site-directed mutagenesis
The BT_1846 gene encoding DPP III enzyme was amplified from the genomic DNA of B. the-
taiotaomicron using PCR with the primers listed in S1 Table. The PCR product was cloned
into NheI and XhoI sites of the pET-21b(+) vector, resulting in a construct containing a hexa-
histidine tag (-LEHHHHHH) at the C-terminal end of the enzyme. Point mutations of the
enzyme were carried out with the QuikChange II XL Site-Directed Mutagenesis kit (Agilent
Technologies) according to the manufacturer’s instructions. The primers designed to intro-
duce C11S, C158S, C189S, C425S, and C450S are listed in S1 Table. Cys-null was prepared by
introducing the point mutations stepwise, starting with C11S.
Enzyme expression
For heterologous expression of wild-type and Cys-null DPP III, Escherichia coli BL21-Codon-
Plus (DE3)-RIL cells were transformed with the appropriate expression vector (encoding the
wild-type or the Cys-null mutant). Further procedure was performed as described for the
human DPP III [14], with the exception that, after inducing expression, the culture was grown
at 37˚C for 4 h. Bacterial cells were harvested by centrifugation at 5000 g at 4˚C for 20 minutes
and stored at -20˚C until purification.
DPP III labelled with selenomethionine (Se-Met) was produced by transforming Escheri-
chia coli B834(DE3) cells with the Cys-null construct. One of the transformed colonies was
inoculated into 10 ml of Luria broth medium supplemented with 100 μgmL-1 ampicillin
and was then grown overnight. The following day, 10 mL of the overnight cell culture was
added into 0.5 L of minimal medium containing 7.5 mM (NH4)2SO4, 8.5 mM NaCl, 22 mM
KH2PO4, 50 mM K2HPO4, 1 mM MgSO4, 20 mM D-glucose monohydrate, 1 μgmL-1 CaCl2,
1 μgmL-1 FeCl2, 0.01 μgmL-1 of trace elements (CuSO4, ZnCl2, MnCl2 and (NH4)2MoO4),
10 μgmL-1 thiamine, 10 μgmL-1 biotin, 100 μgmL-1 ampicillin, 50 mgL-1 of all amino acids
except methionine, and 40 μM methionine. The cells were grown for 8–10 h at 37˚C and 150
rpm until D600nm reached a constant value. At that point, all methionine was depleted, and
incubation was continued without methionine under the same conditions for two more hours.
Protein expression was induced with 0.5 mM isopropyl thio-β-D-galactoside, and 0.125 mM
selenomethionine was added to the cell culture. The growth was continued for 3–4 h, before
harvesting the cells by centrifugation at 5000 g for 20 minutes [15].
Enzyme purification
All of the following procedures were performed at 4˚C. The cells from 2–4 L of culture were
resuspended in up to 50 mL of lysis buffer (5 mL solution per 1 g of pellet), containing 50 mM
Tris-HCl (pH 8.0), 300 mM NaCl, and 10 mM imidazole. The cell suspension was lysed by
sonication and then centrifuged for 45 minutes at 14500 g. The supernatant was filtrated using
Rotilabo-syringe filters with 0.45 μm cut-off (ROTH, Karlsruhe, Germany) to remove all
remaining cell debris and was then applied for affinity chromatography on Ni-NTA resin
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(5 mL pre-packed His-trap FF, GE Healthcare) fitted in an A¨KTA FPLC (GE Healthcare) that
had been equilibrated with the lysis buffer. The affinity column was washed with 25 mL of the
lysis buffer. Protein elution was performed using a 50-mL linear gradient of 10–500 mM imid-
azole in the same buffer. The obtained enzyme sample was then applied to Superdex 200 (26/
60 or 16/60, depending on the sample volume) gel filtration column (GE Healthcare) previ-
ously equilibrated with 50 mM Tris-HCl (pH 7.4) containing 100 mM NaCl. Fractions with
purified protein corresponding to a molecular mass of ~77 kDa were collected and concen-
trated using centrifugal filtration (Amicon 10K; Millipore, Bedford, MA, USA). The purity of
the fractions was analysed by SDS-PAGE (12% gel), and the protein concentration was deter-
mined by measurement at A280 nm, using the theoretical molar extinction coefficient, 99130
M-1cm-1, determined by ProtParam tool on ExPASy SIB Bioinformatics Resource Portal [16].
The homogeneity of the fractions was analysed by isoelectric focusing (IEF) on PhastGel IEF
plates with pH gradient 4–6.5 (GE Healthcare). For long-term storage, the purified enzyme
was kept at –80˚C.
Determination of kinetic parameters
The release of the fluorescent product (2-naphthylamine, 2NA) of enzymatic hydrolysis of
dipeptidyl-2-naphthylamides was used for the initial rate measurements as described by
Abramić et al. [5], and kinetic parameters (Km and kcat) were determined by non-linear regres-
sion, using GraphPad Prism 7.03. Enzymatic reactions were performed at 25˚C and at pH 8.0
(20 mM Tris-HCl), with the dipeptidyl-2-naphthylamide substrate (0.05 μM to 5 μM Arg2-
2NA, 0.6 μM to 40 μM Ala–Arg-2NA, or 0.6 μM to 80 μM Phe-Arg-2NA), and 0.4 nM (with
Arg2-2NA and Ala-Arg-2NA) or 1.3 nM (with Phe-Arg-2NA) wild-type BtDPP III. The
enzyme was preincubated for 2 minutes in 3-mL reaction mixture, and then the reaction
started with the addition of a few microliters of substrate stock solution. Continuous measure-
ment of the fluorescence of the free 2NA was performed for 1 minute by the Agilent Cary
Eclipse fluorescence spectrophotometer (emission wavelength 420 nm, slit width 5 nm; excita-
tion wavelength 332 nm, slit width 10 nm). Enzymatic reactions obeyed the Michaelis-Menten
kinetics (S2 Fig).
Phylogenetic analysis
Databases of bacteria, fungi, nematodes, arthropods, and vertebrates from the UniProt reposi-
tory were analysed for DPP III homologues using the BLAST search tool with B. thetaiotaomi-
cron, yeast, and human counterparts (UniProt KB entries: Q8A6N1, Q08225, and Q9NY33).
Since the databases contained large numbers of homologues, 87 members of the M49 family
were selected for the construction of the phylogenetic tree. The selected sequences comprise
commonly used model organisms together with the representative sequence from each phy-
lum; 19 bacteria, 10 fungi, 11 nematodes, 10 arthropods and 37 vertebrate homologues. The
full names of all species with protein accession numbers are given in S2 Table. Multiple align-
ment of 87 DPP III protein sequences was performed using ClustalW [17]. The maximum like-
lihood (ML) tree based on the ClustalW alignment was obtained with the PhyML 3.0 using
JTT amino acid substitution model [18]. The phylogenetic tree was displayed with FigTree
v1.40 [19] and adjusted in CorelDRAW 12 software [20].
Crystallization and data collection
Crystallization was done using an Oryx8 robot (Douglas Instruments, UK) by vapour diffusion
in sitting drops by mixing 0.5 μL of protein solution and 0.5 μL of crystallization solution at
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20˚C. Six different commercial screens were used: Midas, JCSG+, PGA, and Morpheus from
Molecular Dimensions (Newmarket, UK), the PACT Suite from Qiagen (Hilden, Germany),
and Index from Hampton Research (California, USA). The first crystals were obtained in 0.2
M ammonium acetate, 0.1 M MES pH 6.5, 30% v/v glycerol ethoxylate (Midas G7) using Cys-
null protein concentrated to 16.6 mgmL-1. Se-Met labelled Cys-null protein concentrated to
28 mgmL-1 produced microcrystals in 0.2 M ammonium chloride, 0.1 M HEPES pH 7.5 and
25% v/v glycerol ethoxylate (Midas H4). These microcrystals were used to prepare a seed stock
solution. The seed stock and the working solution were prepared with Seed Bead (Hampton
Research) as per the manufacturer’s protocol. Further screening was done by mixing 0.5 μL of
protein solution and 0.5 μL of crystallization solution and 0.25 μL of seeding working solution
(20x diluted seed stock solution).
Crystals of Se-Met labelled Cys-null protein were obtained in several new conditions: 0.2 M
ammonium acetate, 0.1 M MES pH 6.5, 30% glycerol ethoxylate (Midas G7), 0.2 M NaCl, 0.1
M sodium cacodylate pH 6.5, 2.0 M (NH4)2SO4 (JCSG+ E2), 0.1 M bicine, 10% w/v PEG
20000, 2% v/v dioxane pH 9.0 (JCSG+ C10), and 0.1 M Bis-Tris pH 5.5, 2.0 M (NH4)2SO4
(JCSG+ G11). The best diffracting crystals were grown in Midas G7 condition. For the crystal-
lization of the wild-type, the protein sample was concentrated to 18.5 mgmL-1 and a few crys-
tals were obtained in the JCSG+ E2 condition.
We tried to crystallize the complexes of all prepared protein constructs with Tyr-Phe-
NHOH. This compound was chosen because it is a substrate analogue of DPP III, previously
shown to be a potent competitive inhibitor of BtDPP III [13]. The inhibitor was dissolved in
the same buffer as the protein and mixed in an approximately 1:30 protein:inhibitor molar
ratio, after which it was incubated for 20 minutes at 4˚C. This mixture was used in crystalliza-
tion trials with four known crystallization conditions, as described for Se-Met labelled Cys-
null protein. One crystal was obtained with Se-Met labelled Cys-null DPP III in the JCSG+ E2
condition. Despite our extensive efforts, we were not able to reproduce the crystallization of
the protein in either the open or the closed conformation.
The crystals were flash-cooled with liquid N2, and all of the diffraction experiments were
carried out at 100 K at Elettra Sincrotrone Trieste (Trieste, Italy) with a PILATUS 2M detector.
The single-wavelength anomalous diffraction (SAD) experiment with Se-Met labelled Cys-null
crystal was performed at 0.9718 Å wavelength. We collected 720 images, covering 360˚ at a res-
olution of 1.90 Å. Datasets for the wild-type and the structure in the closed form were collected
at 0.976 Å wavelength, at resolutions of 2.40 and 3.29 Å, respectively. Data collection and
refinement statistics are summarized in Table 1.
Phasing, model building, and refinement
Data processing was performed with XDS [22], and data scaling with Aimless [23] within the
CCP4 software suite [24]. Randomly selected 5% of reflections were excluded from all refine-
ments and used to calculate Rfree.
Initial single-wavelength (0.9718 Å) anomalous diffraction phases for the Se-Met labelled
Cys-null DPP III were obtained with SHELX [25]. SHELXD found nine selenium atoms in the
asymmetric unit. These atoms were then used to determine the initial phases, and a poly-Ala
model was built using the SHELXE program. The electron density map was further improved
using the Parrot program [26] within the CCP4 software suite [24]. BUCCANEER software
[27] was used to build an initial Cys-null DPP III model. This model was further refined using
the programs REFMAC [28, 29] and PHENIX [30]. The COOT program [31] was used for
model fitting and real space refinement using σA-weighted 2Fo-Fc and Fo-Fc electron density
Structure of a bacterial dipeptidyl peptidase III
PLOS ONE | https://doi.org/10.1371/journal.pone.0187295 November 2, 2017 5 / 19
maps. Translation, rotation, and screw-rotation (TLS) parameterization of anisotropic dis-
placement was used in the last refinement step [32]. Four TLS groups were defined: 24–328,
329–414, 415–623, and 624–675.
The structures of the wild-type protein and the protein in the closed form were deter-
mined by molecular replacement using the MOLREP program [33] within the CCP4 soft-
ware suite [24], employing the structure of Cys-null DPP III as the model structure. The
refinement procedure was the same as for the Cys-null structure, except that no TLS refine-
ment was used for the lower resolution structure that was in the closed form. Structure
determination and refinement statistics are given in Table 1. The final coordinates and
structure factors have been deposited in the Protein Data Bank (accession number for the
wild-type, structure in the closed form and the Cys-null are 5NA7, 5NA8 and 5NA6,
respectively).
Table 1. Data collection, structure determination, and refinement statisticsa.
Wild-type Cys-null Structure in the closed form
Crystal parameters
Resolution (Å) 2.4 1.9 3.29
Space group P3121 P3121 P21212
Unit cell parameters
a, b, c (Å) 103.5, 103.5, 141.0 103.4, 103.4, 141.2 123.6, 176.3, 74.1
α, β, γ (˚) 90.0, 90.0, 120 90.0, 90.0, 120 90, 90, 90
Matthews coefficient (Å3/Da) 2.81 2.83 2.62
Solvent content (%) 56.4 56.5 53.0
Data collection
Completeness (%) 99.9 (99.5) 99.7 (96.6) 99.0 (87.1)
No. of unique reflections 34694 69127 25217
I/σ(I) 8.4 (2.8) 15.7 (2.5) 7.8 (3.0)
Rmerge 0.161 (0.594) 0.087 (0.724) 0.229 (0.592)
CC1/2 0.99 (0.822) 0.998 (0.846) 0.974 (0.871)
Redundancy 5.30 (5.50) 6.90 (6.70) 5.30 (4.50)
Wilson B-factor (Å2) 25.3 25.8 47.3
Refinement
R / Rfree 0.202/0.244 0.173/0.200 0.207/0.251
RMSD bonds length (Å) 0.005 0.008 0.002
Average B factor 29.3 31.3 41.0
Number of molecules in AU 1 1 2
No. of atoms
Protein 5173 5154 5100/5098
Zinc ion 1 1 2
Water molecules 382 575 0
Ramachandran analysisb
Favoured (%)/n 98 98 98
Allowed (%)/n 2 2 2
Outlier (%)/n 0 0 0
The abbreviations RMSD and AU stand for root-mean-square deviation and asymmetric unit, respectively.
a Data for the highest resolution shell are given in parentheses.
b Defined by validation program MOLPROBITY [21].
https://doi.org/10.1371/journal.pone.0187295.t001
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Results and discussion
Protein sample preparation and crystallization
Wild-type BtDPP III was produced in Escherichia coli and purified employing Ni-NTA affinity
chromatography, as described under “Materials and methods”. The purified wild-type protein
was analysed using SDS-PAGE and IEF. While SDS-PAGE exhibited a single protein band
(Fig 1A), IEF showed three bands (Fig 1B, position 1). Because the protein contains five cyste-
ine residues, we suspected that the oxidation of the side chain thiol group could be the reason
behind the observed heterogeneity. The oxidation of a cysteine thiol group results in the for-
mation of a sulfenic, sulfinic or sulfonic acid derivative, leading to additional negative charges.
Since we failed to obtain crystals from the purified wild-type protein, we assumed that the het-
erogeneity introduced by the oxidation of thiol groups had impeded crystallization. In order to
identify the cysteine(s) responsible for the charge heterogeneity, we substituted the cysteine
residues with serine by site-directed mutagenesis and subsequently purified the recombinant
proteins. The five variants, i.e. C11S, C158S, C189S, C425S, and C450S were subjected to IEF
(Fig 1B, lanes 2–10). It was observed that sample C11S is less heterogenic than the wild-type,
showing one form in higher concentration, but all three forms were still present (Fig 1B, lanes
2 and 3). Also, a slight difference was observed in the case of C450S, where two forms were
present in higher concentrations (Fig 1B, lane 10). The other variants were comparable to the
wild-type protein. Thus, our results suggested that the observed charge heterogeneity in the
purified BtDPP III was not caused by the oxidation of a single thiol group, but rather the out-
come of oxidative modification of several thiol groups. Therefore, we prepared an additional
variant with all five cysteine residues replaced by serine (Cys-null variant). As shown in Fig 1B
(lane 11) this variant showed significantly improved homogeneity with one dominant protein
form (Fig 1B, position 11).
Initial crystallization screening was done using the wild-type protein. As no crystals were
obtained, the same crystallization screening was done with a more homogeneous Cys-null
Fig 1. SDS-PAGE and isoelectric focusing analysis of the purified BtDPP III protein variants. (A) SDS-PAGE of purified recombinant wild-type DPP
III; (B) Isoelectric focusing analysis of purified wild-type (lane 1) and cysteine variants: C11S (lanes 2–3), C158S (lanes 4–5), C189S (lanes 6–7), C425S
(lanes 8–9), C450S (lane 10) and Cys-null (lane 11). Proteins were visualized by Coomassie Blue staining.
https://doi.org/10.1371/journal.pone.0187295.g001
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protein sample. The first crystals of the Cys-null protein were obtained in the G7 condition of
the Midas screen. Microcrystals of the Se-Met labelled Cys-null protein were obtained in the
H4 condition of the Midas screen (Molecular Dimensions, Newmarket, UK) and were then
used to prepare the seed solution. Further crystallization screens were prepared using micro-
seeding, and crystals of the Se-Met-labelled Cys-null protein were obtained in four new condi-
tions: JCSG+ C10, E2, G11, and Midas G7. The best diffracting crystal was used for the
complete data collection, and the crystal structure was solved using SAD at 1.9 Å resolution.
The wild-type DPP III crystals were obtained only after the initial crystallization conditions
with Se-Met labelled Cys-null protein were determined. Out of more than 100 drops prepared
using these four conditions, just a few crystals of the wild-type protein grew in the E2 condi-
tion of the JCSG+ screen (Molecular Dimensions, Newmarket, UK), while other drops did not
yield any crystals. The structure was solved at 2.4 Å resolution using molecular replacement,
with the structure of the Cys-null variant as a search model. Both proteins crystallized in space
group P3121, with one molecule in the asymmetric unit. By superimposing the wild-type on
the Cys-null structures, we confirmed that the replacement of cysteine residues or the incorpo-
ration of Se-Met did not change the protein structure (backbone RMSD 0.15 Å). Therefore,
only the wild-type structure was considered in further discussion. To obtain a complexed
structure, we used the potent competitive inhibitor Tyr-Phe-NHOH. We succeeded in grow-
ing only one crystal in the presence of Tyr-Phe-NHOH. This crystal belonged to space group
P21212, with two protein molecules in the asymmetric unit. The structure was solved at 3.3 Å
resolution using molecular replacement, with the separated structural domains of the Cys-null
protein as a model. It was not possible to locate the inhibitor molecule in the electron density
maps, but since the conformation changed from open (wild-type) to closed, this structure was
included in further consideration.
Crystal structure of BtDPP III and its comparison with its eukaryotic
counterparts
Despite a low sequence identity (17–21%), the overall structure of BtDPP III is very similar to
the previously reported crystal structures of human and yeast DPP III [11, 12] and consists of
two domains separated by a wide cleft (Fig 2). The upper structural domain (C-terminal) is
mostly helical, while the lower one contains mixed secondary structural elements with a five-
stranded β-barrel core (Fig 2). A search for similar folds, performed by structure alignment
using PDBeFold [34], did not yield any other matches except for the already known structures
of yeast and human DPP III. The catalytic zinc ion is positioned in the lower part of the upper
structural domain, coordinated by His448, His453, and Glu476. The two histidine residues are
part of the conserved motif HEXXGH of the M49 family, and Glu476 is part of the second
active site motif EEXR(K)AE(D). Although the zinc ion identity was not confirmed experi-
mentally in BtDPP III structures, zinc was the most likely candidate as a catalytic ion for sev-
eral reasons. Firstly, zinc content was previously determined in DPP III purified from human
placenta and in the recombinant rat enzyme (expressed in E. coli) by atomic absorption spec-
trometry, revealing that DPP III contains 1 mole of zinc per mole of protein [9]. Furthermore,
with site-directed mutagenesis of rat DPP III and zinc content determination in the produced
DPP III protein variants, three amino acids that coordinate the active-site zinc ion were deter-
mined [35]. Those were His450 and His455 from the HELLGH motif, and Glu508 from the
EECRAE motif. Additionally, the zinc binding site in DPP III crystal structures resembles the
zinc binding site of many other zinc-peptidases, including thermolysin and neprilysin [11].
The coordination of the zinc ion is square pyramidal with two water molecules in the remain-
ing positions (Fig 2). In contrast, in both human and yeast DPP III, zinc exhibits a tetrahedral
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coordination with a single water molecule that is considered to be important for the generally
accepted catalytic mechanism involving water activation by Glu461 [11]. It is interesting that
in the case of BtDPP III, the corresponding Glu449 does not point toward either of the two
zinc-coordinated water molecules. The function of this glutamic acid in the previously pro-
posed catalytic mechanism for DPP III is to activate the water molecule that is bound to the
zinc ion for the nucleophilic attack on the peptide bond of the substrate [11].
The superimposed protein backbones of ligand-free bacterial and ligand-free human DPP
III structures gave rise to an RMSD value of 4.41 Å. This high RMSD value is a consequence of
a difference in cleft size between human and bacterial DPP III. Namely, human DPP III is
more open than the bacterial enzyme. Using the PyMol software, BtDPP III was divided into
an upper and a lower domain, which were subsequently treated as separate objects. Superposi-
tion of the upper domain of BtDPP III (amino acids 328–364 and 404–626) with the corre-
sponding upper domain of the human enzyme gave rise to an RMSD value of 3.0 Å. An
analogous alignment of the respective lower domains of the bacterial (amino acids 24–327,
365–403 and 627–675) and human enzymes yielded an RMSD value of 2.0 Å. This method of
comparison thus revealed a conservation of tertiary structures in a manner that is significantly
Fig 2. Structures of ligand-free Bt, yeast and human DPP III with their respective zinc binding sites. Zinc binding sites are shown in grey squares.
Amino acids coordinating the zinc ions (shown as grey spheres) and the glutamic acid residues essential for enzyme activity are shown in stick
representations. The figure was prepared using the PyMol program (http://www.pymol.org/), and the PDB-deposited crystal structures of the yeast (PDB
ID 3csk) and human DPP III (PDB ID 3fvy).
https://doi.org/10.1371/journal.pone.0187295.g002
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clearer than a simple superposition of the entire proteins (Fig 3). Furthermore, a structural
comparison revealed two significant differences. The loop in the upper structural domain
between the two active-site motifs involved in zinc binding is 30 amino acids shorter in the
bacterial protein compared to its human counterpart. In the lower domain, there is a two-
stranded β-sheet (221–242, 21 residues), whereas in the human DPP III a four-stranded β-
sheet and an extra α-helix (197–251, 54 residues) are found (Fig 3A). The difference in length
between the BtDPP III (675 amino acids) and human DPP III (737 amino acids) is 62 amino
acids and corresponds to the difference in length between these two regions. Due to the high
structural similarity between human and yeast enzymes (RMSD 1.36 Å), the same differences
between bacterial and yeast DPP III are observed (Fig 3B).
We reported earlier, based on the primary structure analysis of the M49 family members,
that the length of the spacer region between the two evolutionarily conserved active-site motifs
is much shorter in bacterial proteins, compared to eukaryotic DPPs III [10]. From our struc-
tural studies, it is now obvious that this region comprises an additional loop in human and
yeast DPP III. In this loop, the human enzyme contains the so-called E480TGE motif, which is
considered important for protein interaction with Keap1 and required for the activation of the
Keap1-Nrf2 signalling pathway [8]. Thus, we performed a phylogenetic analysis of the M49
family of enzymes to determine the emergence of the loop between the two active-site motifs
Fig 3. Superposition of ligand-free BtDPP III on human and yeast proteins. The upper and lower domains were separately superimposed to the
corresponding domains of human (A) and yeast (B) DPP III. Their structures are shown in cartoon representation: bacterial in magenta, human in green,
and yeast in cyan. The black ellipses indicate the areas of the two main differences between the superimposed structures. The figure was prepared using
the PyMol program (http://www.pymol.org/).
https://doi.org/10.1371/journal.pone.0187295.g003
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and of the ETGE motif within this loop, respectively. The obtained phylogenetic tree, con-
structed based on a multiple sequence alignment of 87 selected sequences, is consistent with
conventional species evolution (Fig 4). As can be seen from Figs 4 and 5, the insertion between
the two active-site motifs occurred before the fungi/metazoa split. However, the ETGE motif is
conserved in vertebrate homologues only, and it was not found in invertebrates, fungi, or bac-
teria (Fig 5). Interestingly, Gacesa et al. reported that the Keap1-Nrf2 pathway evolved after
the eukarya separated from the prokarya, but prior to the fungal-metazoan split [36]. This sug-
gests that DPP III’s moonlighting activity, i.e. the modulatory effect on the Keap1-Nrf2 path-
way, evolved much later, when the Keap1-Nrf2 pathway was already present.
It has recently been shown that yeast DPP III does not prefer the canonical synthetic sub-
strate of mammalian DPP III, Arg-Arg-arylamide [37]. In addition, it was reported that
Asp496 situated in the S2 subsite of the human enzyme is an important determinant in the
selectivity of human DPP III for Arg-Arg-2-naphthylamide (Arg2-2NA) [38]. The superposi-
tion of the crystal structures of BtDPP III and hDPP III reveals that the residue that structurally
corresponds to Asp496 is Asp465 in BtDPP III. Therefore, to investigate experimentally
whether the bacterial enzyme shows preference for diarginyl arylamide, we determined the
kinetic parameters of BtDPP III for the hydrolysis of three dipeptidyl naphthylamide sub-
strates: Arg2-2NA, Ala-Arg-2NA, and Phe-Arg-2NA (Table 2), which had previously been
Fig 4. Phylogenetic tree of the M49 family. The tree is based on a multiple sequence alignment and
maximum likelihood analysis of 87 peptidases of the M49 family. The branch support values are indicated at
the major branch points. Species abbreviations are given in S2 Table. Arrows represent the appearance of the
loop between the two conserved active-site motifs in the upper domain and the emergence of the ETGE motif.
https://doi.org/10.1371/journal.pone.0187295.g004
Structure of a bacterial dipeptidyl peptidase III
PLOS ONE | https://doi.org/10.1371/journal.pone.0187295 November 2, 2017 11 / 19
shown to be useful in discriminating between the substrate specificities of human and yeast
DPP III [37]. Thus, we confirmed experimentally that BtDPP III also shows a preference for
Arg2-2NA with an 8- and 29-fold higher catalytic efficiency (kcat/Km) for this substrate than
for Ala-Arg-2NA and Phe-Arg-2NA, respectively. In the yeast enzyme, Gly505 is the structural
Fig 5. A section of a multiple sequence alignment of M49 peptidases. Thirty M49 peptidases were selected from different eukaryotic and bacterial
species. The active-site motifs I and II as well as ETGE motif are framed. The loop between the two conserved active-site motifs of the human M49
peptidase is highlighted in grey. The full names of the species are given in S2 Table.
https://doi.org/10.1371/journal.pone.0187295.g005
Table 2. Kinetic analysis of wild-type BtDPP IIIa.
Substrate Km (μM) kcat (s-1) kcat/Km (mM-1s-1)
Arg2-2NA 0.359 ± 0.030 0.384 ± 0.009 1070
Ala-Arg-2NA 3.87 ± 0.20 0.537 ± 0.008 139
Phe-Arg-2NA 4.85 ± 0.37 0.178 ± 0.004 36.8
aThe kinetic parameters were determined from the initial reaction rates at 25˚C, as described under “Materials and methods”. Km and kcat values are the
averages of three determinations ± SD.
https://doi.org/10.1371/journal.pone.0187295.t002
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counterpart of human Asp496. In our recent study, a replacement of Gly505 with Asp yielded
a protein variant of yeast DPP III which was selective for Arg2-2NA [37].
X-ray structure of BtDPP III in the closed conformation
For human DPP III, it was shown that a closed conformation is favoured upon ligand binding
to the lower structural domain accompanied by a large structural domain movement [12, 39].
To verify if this conformational change is also characteristic for bacterial DPP III, we crystal-
lized the Cys-null variant in the presence of the competitive inhibitor Tyr-Phe-NHOH. The
solved crystal structure revealed that the protein is in the closed conformation. This dipeptidyl
hydroxamic acid is a substrate analogue of DPP III and a potent inhibitor of the human and
bacterial enzymes [13].
In contrast to ligand-free bacterial DPP III (open form), in the presence of the inhibitor, the
closed conformation was obtained, with the binding cleft closed (Fig 6). According to the Dyn-
Dom program [40, 41], this conformational change can be described by a 28˚ rotation of one
structural domain relative to the other. A superposition of the backbone atoms of the upper
and lower domains of the wild-type and the structure in the closed form results in RMSD val-
ues of 0.41 and 0.26 Å, respectively. This indicates the absence of large conformational changes
within the domains. According to the DynDom program, the bending regions are 330–334,
Fig 6. Surface representation of the ligand-free structure and the structure of the closed form of BtDPP III. The upper structural domain is shown
in blue and the lower one in magenta. Amino acids coloured in red are: zinc binding residues (His448, His453, and Glu476), glutamic acid essential for
enzyme activity (Glu449), and structurally equivalent amino acids residues (Glu307, Tyr309, Thr380, Ile382, Gly383, Asn385, Asn388, Asp465, His533,
and Tyr627) that were shown to interact with peptide substrates in human DPP III. The figure was prepared using the PyMol program (http://www.pymol.
org/). The illustration showing domain movement in human DPP III, given in the square, was taken from Bezerra et al. [12].
https://doi.org/10.1371/journal.pone.0187295.g006
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357–366, 414–418, and 618–623. Our results are in agreement with the data reported for
human DPP III, where a large domain movement and formation of the closed conformation
was noticed for the first time [12]. Compared to the human enzyme, a smaller rotation of
domains (28˚ vs. 57˚) was observed in BtDPP III in the closed conformation (Fig 6).
The zinc ion in the active site is coordinated by His448, His453 and Glu476, as in the open
form. Instead of the two water molecules coordinated to the zinc ion in the ligand-free struc-
ture, in the closed form we observed a large undefined electron density (Fig 7A). Since the pro-
tein in the closed form was obtained by cocrystallization with the inhibitor Tyr-Phe-NHOH,
we tried to fit this molecule into the electron density map. However, after several cycles of
refinement and employment of different orientations of the inhibitor, we realised that electron
density was too small to fit the whole inhibitor molecule (Fig 7B). Even by assuming only par-
tial occupancy of the inhibitor, we did not obtain a satisfying result. In the crystal structure of
the Cys-null variant (open form), one Tris molecule, contained in the storage buffer, was
bound to the zinc ion. As the same protein solution was used to obtain the structure in the
closed form, we also tried to fit a Tris molecule in the undefined electron density. After several
cycles of refinement, however, there was still extra electron density around the Tris molecule
(Fig 7C). All other molecules present in the crystallization solution (sodium cacodylate and
ammonium sulphate) were also too small to occupy the undefined electron density. As the res-
olution of the structure in the closed form is only 3.3 Å, and the electron density is not well-
defined, we cannot determine the source of the observed electron density near the zinc ion.
Five evolutionarily conserved regions in M49 peptidases are embedded in a stretch of about
300 amino acids [10] and situated on both the lower (region 1 and region 2) and the upper
protein domains (regions 3 and 4, comprising zinc-binding motifs, and region 5) [38]. S1 Fig
illustrates conserved regions on the BtDPP III structure. The active site of DPP III consists of
the active-site zinc ion, the zinc-binding site and the substrate binding site [11, 12]. It is
formed by the constituents of all five conserved regions of the M49 family, i.e. by the amino
acid residues from the lower and the upper protein domains [12]. It was shown that the pep-
tide substrate is completely buried between the two protein domains (lobes) of human DPP III
[12, 39].
Fig 7. Overall cartoon representation of the active site in BtDPP III structure in the closed form. 2mFo-DFc electron density at 1 σ (blue) and mFo-
DFc electron density at 3 σ (green) correspond to the substrate-binding position. The upper structural domain is shown in blue, the lower one in magenta,
and the zinc atom as a grey sphere. The amino acids binding the zinc ion, Tris, and Tyr-Phe-NHOH are shown in stick representation. (A) Electron density
map in the active site; (B) electron density with Tyr-Phe-NHOH included in the refinement; (C) electron density with Tris included in the refinement. The
figure was prepared using the PyMol program (http://www.pymol.org/).
https://doi.org/10.1371/journal.pone.0187295.g007
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Even before the crystal structure of human DPP III ligand complex was resolved, our obser-
vation that Cys176, a residue from the lower domain, quite distant from the active centre (44
Å apart from the catalytic zinc ion in the crystal structure of ligand-free human DPP III), is
responsible for the fast inactivation by the organomercurial compound, provided the evidence
that the active site of human DPP III comprises both protein domains, which in the active
form of the enzyme need to be in close contact [42].
Considering the above-mentioned evidence, it could be predicted that DPP III in the open
conformation does not have catalytic activity.
Our data on the open and closed conformation of BtDPP III indicate that large protein flex-
ibility might be conserved in the M49 family. Furthermore, these results suggest that ligand
binding to the prokaryotic orthologue, similarly to its human counterpart, might induce a
large domain motion and the formation of a closed active site, which was previously reported
to be a prerequisite for the catalytic activity of these metallopeptidases.
Recently, Kumar et al. have solved the crystal structures of the inactive E451A variant of
human DPP III complexed with three opioid peptides (Met- and Leu-enkephalin, endomor-
phin-2), as well as with the vasoconstrictor octapeptide angiotensin II [39]. They confirmed
the previously reported peptide inhibitor (tynorphin) binding mode and the large domain
motion of the human enzyme upon ligand binding [12]. Based on the analysis of enzyme-sub-
strate interactions in these structures, these authors concluded that the general peptide binding
Fig 8. Superposition of the active sites of BtDPP III and hDPP III with the bound tynorphin. The human DPP III ligand (tynorphin, VVYPW) is shown
in yellow. The amino acids that make polar interactions with the peptide substrate (dashed lines) and the conserved Asp496 that is important for the
substrate specificity are shown as stick models (hDPPIII and BtDPPIII in green and magenta, respectively). The figure was prepared using the PyMol
program (http://www.pymol.org/).
https://doi.org/10.1371/journal.pone.0187295.g008
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mode of human DPP III comprises extensive polar contacts of the N-terminal peptide residues
and the formation of β-type interactions with the core of the enzyme [39]. We compared the
crystal structures of bacterial and human DPP III and found that most amino acid residues
that interact with tynorphin in the human enzyme were structurally conserved in BtDPP III,
suggesting that bacterial DPP III also has the potential to interact with oligopeptides. The
exceptions are: Ile386, Ala388, and Arg669 that correspond to Thr380, Ile382 and Tyr627,
respectively, in BtDPP III (Fig 8). In yeast DPP III, as opposed to the human enzyme, only one
amino acid residue from those interacting with tynorphin is not structurally conserved:
Gly505 corresponding to Asp496 (not shown).
Conclusions
We solved the crystal structures of DPP III (metallopeptidase of the M49 family) from the
human gut symbiont B. thetaiotaomicron. These structures revealed a two-domain protein that
exists in an open (ligand-free) and a closed conformation. The overall protein fold is, despite a
low sequence similarity, very similar to that of the human and yeast orthologues. However,
some significant structural differences were observed in both domains. The loop in the upper
structural domain between the two active-site motifs involved in zinc binding is much (30
amino acids) shorter in the bacterial protein. By using a phylogenetic analysis, we have shown
that this long insertion between the zinc binding motifs occurred before the fungal-metazoan
split, and that only vertebrate homologues contain the ETGE motif, considered important for
the interaction with the Keap1 protein and for the activation of the Keap1-Nrf2 signalling
pathway.
The comparison of BtDPP III with its human counterpart further revealed Asp465 as the
residue corresponding to Asp496 of hDPP III, which is proven as the structural determinant of
the human enzyme substrate selectivity for diarginyl-arylamide [38]. Our data on the open
and closed conformations of BtDPP III indicate that large protein flexibility might be con-
served in the M49 family.
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